VectorY Appoints Michael Wyzga as CFO and adds Jean Franchi to its Board of Directors

Amsterdam, The Netherlands, 20 March 2023 – VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of neurodegenerative diseases, today announces the appointment of Michael Wyzga as Chief Financial Officer (CFO) and Jean Franchi as Independent Board member and Chair of the Audit Committee.

Michael Wyzga most recently served as the CFO of Yumanity Therapeutics, a Nasdaq-listed clinical stage biopharmaceutical company developing innovative disease-modifying therapies for neurodegenerative diseases, where he managed the sale of assets to Janssen Phamaceutica, part of J&J, and a merger with Kineta. Prior to Yumanity Therapeutics, Michael has over a decade of experience in several investment banking roles, including Needham & Company and Citigroup.

Jean Franchi has over 30 years of experience in biotech operations, from pre-commercial to global commercial companies. She is currently CFO at Replimune, a company developing tumor-directed oncolytic immunotherapies. Jean previously served in the same role at Merrimack Pharmaceuticals, Dimension Therapeutics and Good Start Genetics, and was also Senior Vice President of Corporate Finance at Genzyme.

“We are pleased to welcome Mike as our new CFO and Jean as an Independent Board Member. They bring a wealth of experience in financial strategy and operational effectiveness in the healthcare and biotech industry, which will help tremendously as we advance to the next phase of our growth and expand our global presence to the US,” said Sander van Deventer, Chief Executive Officer of VectorY.

“I am excited to join this experienced team at such a pivotal time, ahead of the Company’s lead candidate moving into the clinic. It is impressive to see how much VectorY has advanced its platform technology, and I am convinced of the Company’s potential to truly change the therapeutic landscape in ALS and other devastating neurodegenerative diseases,” said Michael Wyzga, Chief Financial Officer of VectorY.

“The team at VectorY has previously developed two commercial gene therapies and is therefore well positioned to translate its vectorized antibody platform into disease-modifying therapies. I am delighted to join the team to help realize this potential,” said Jean Franchi, Independent Board Member of VectorY.

The new appointments follow the strong growth of VectorY since its inception in 2020 and support the company’s strategy to rapidly advance its innovative pipeline towards the clinic.